Further evidence on this matter is provided by the observation of a more vigorous pro-inflammatory response of CD4+CD20+ T cells compared to CD20− T cells to the CNS antigens myelin oligodendrocyte glycoprotein (MOG) and myelin basic protein (MBP), with no difference in CD20+ T cells reactivity between RR-MS patients and HD, except for a non-significant trend to an increased MBP reactivity in RR-MS (13.6% vs. 6.6%) [13]. The gene discussed is CD4; the disease is myeloid sarcoma.